Upcoming Event: Day 3 of the ADRD Summit 2025 will be virtually held on June 2, 1:00 - 4:00 PM EDT
View the ADRD Summit 2025 Agenda
Click here for information on how to register and join: ADRD Summit 2025 Day 3
For assistance with your registration, please email adrdsummit2025@ninds.nih.gov
Access the Videocast Archive for Days 1 & 2: Watch Day1 and Watch Day 2
What is AD/ADRD?
Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) refers to the most common forms of dementia. Dementia likely affects more than 6 million people in the U.S. and more than 55 million people worldwide. Currently, there are no known treatments to prevent or stop the progression of dementia. The toll on individuals, caregivers and society is enormous and will increase as the population ages unless effective interventions are developed. NINDS collaborates with NIH’s National Institute on Aging (NIA), the lead NIH Institute for Alzheimer’s disease (AD) research and for NIH's response to the National Plan to Address Alzheimer’s Disease, to establish research priorities and fund biomedical research to decrease the burden of dementia on individuals, families, and communities.
While AD is the most common dementia diagnosis, ADRDs share many cognitive and pathological features with and can be difficult to distinguish from AD. In fact, more often than not, patients with a clinical diagnosis of Alzheimer’s disease have different mixtures of brain pathologies, complicating both the diagnosis, as well as treatment. A special video testimonial to raise awareness of the disease burden on patients with AD/ADRD and their caregivers titled “Voices of AD/ADRD” was presented at the NINDS ADRD Summit 2022.
NINDS and NIA continue to partner in AD/ADRD research planning and implementation, and we urge the research community to join in our efforts to accelerate scientific progress toward reducing the enormous burden and cost of dementia.
No RFA is needed to apply!! NINDS special AD/ADRD payline applies to investigator-Initiated research applications to the NIH Parent R01 and the NINDS R21 (PA-21-219)
Funding Opportunity Announcements
Currently Active
Training
NINDS Alzheimer’s Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award (K99/R00 Independent Clinical Trial Not Allowed) (PAR-24-213)
Due date: NIH Standard due dates; Contact PO: Amber McCartney
Translational
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (Small Business Innovation Research; R43/R44 Clinical Trial Optional) (PAR-22-196)
Due date: NIH Standard due dates; Contact PO: Annette Gilchrist
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (Small Business Technology Transfer; R41/R42 Clinical Trial Optional) (PAR-22-197)
Due date: NIH Standard due dates; Contact PO: Annette Gilchrist
Planned Initiatives
We are excited to share with you the research concepts approved by NINDS Council. Please note that this page will be periodically updated with links when funding opportunities are published. These are also announced via our email listserv (to join the NINDS AD/ADRD listserv, please email kiara.bates@nih.gov).
Please note that an approved concept listed below does not necessarily indicate an award mechanism or funding allocation is imminent or will happen. The NOFO is only official when published in the NIH Guide.
Integrative Multiomics Profiling for Lewy Body Dementia- This initiative is designed to support research to conduct genetic and molecular characterization of LBD. This may include whole genome sequencing, longitudinal bulk-transcriptomics, longitudinal matched plasma, and cerebrospinal fluid (CSF) proteomic analysis, and post-mortem single-cell RNA sequencing, which will be generated and paired with harmonized longitudinal clinical data. Contact PO: Christine Swanson-Fischer
IND-enabling Studies and Clinical Trials for Genome Editing Therapeutics for Alzheimer's Disease and Alzheimer's Disease-Related Dementias - This initiative support Investigational New Drug (IND) enabling studies for the preparation and submission of an IND for a genome editing therapeutics for ADRD, and optional small delayed-onset first in human Phase I clinical trial. Contact PO: Timothy LaVaute
Recently Closed Funding Opportunities
Basic Disease Mechanisms
ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed) (PAR-24-270)
Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings (R01 - Clinical Trial Not Allowed) (PAR-24-234)
Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD, and other ADRDs (R01 - Clinical Trial Not Allowed) (PAR-24-148)
Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) (PAR-24-147)
Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID) (R01 - Clinical Trial Not Allowed) (PAR-24-196)
Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) after anti-Aβ immunotherapy (R01 - Clinical Trial Not Allowed) (PAR-24-198)
Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed) (PAR-24-203)
Interaction Between Environmental Factors and Lewy Body Dementia (R01 - Clinical Trial Not Allowed) (PAR-24-249)
VCID Center Without Walls for Understanding and Leveraging Small Vessel Cerebrovascular Disease Mechanisms in ADRD (R01 - Clinical Trial Not Allowed) (RFA-NS-24-027)
Blood Brain Barrier Response to Antibodies Targeting Beta-Amyloid (R01 - Clinical Trial Not Allowed) (PAR-23-140)
Role of Environmental Stress in the Health Inequities of Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed) (RFA-NS-24-024)
Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) (PAR-23-211)
Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD, and other ADRDs (R01 - Clinical Trial Not Allowed) (PAR-23-212)
Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed) (PAR-23-214)
Mechanisms of Cognitive Fluctuations in ADRD Populations (R01 - Clinical Trial Optional) (RFA-NS-25-014)
Clinical
Safety and Efficacy of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Lewy Body Dementia and Amyloid-Beta Pathology (U01 - Clinical Trial Required) (RFA-NS-25-010)
Clinical Trial Readiness to Understand and Develop Solutions to Social, Ethical, Behavioral Implications and Barriers to Health Equity in ADRD (R01 - Clinical Trial Not Allowed) (RFA-NS-25-013)
Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required) (RFA-NS-24-013)
Tools and Resources to Understand the Vascular Pathophysiology of in vivo Neuroimaging Findings in ARIA (U24 - Clinical Trials Not Allowed) (RFA-NS-24-034)
Using Multimodal Biomarkers to Differentially Diagnose ADRDs for Clinical Trials (U19 Clinical Trial Optional) (RFA-NS-24-001)
Validating digital health technologies for monitoring biomarkers in ADRD clinical trials (R61/R33 - Clinical Trials Optional) (RFA-NS-24-026)
Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes (U01 - Clinical Trial Not Allowed) (RFA-NS-24-003)
Training
NINDS Institutional AD/ADRD Research Training Program (T32 Clinical Trial Not Allowed) (PAR-23-113)
Translational
Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed) (RFA-NS-24-037)
Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed) (RFA-NS-25-011)
Simultaneous and Synergistic Multi-Target Validation for Alzheimer’s Disease-Related Dementias (R61/R33 Clinical Trial not allowed) (PAR-23-195)
Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) (RFA-NS-24-010)
Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed) (RFA-NS-24-009)
Center without Walls for PET Ligand Development for Alzheimer's disease-related dementias (ADRDs) (U19 - Clinical Trial Optional) (RFA-NS-19-014)
ADRD Models
Development & Characterization of Experimental models of post-TBI ADRD (R01 - Clinical Trial Not Allowed) (PAR-23-218)
Development and Validation of Models for ADRD (R61/R33 - Clinical Trial Not Allowed) (PAR-23-154)
Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed) (RFA-NS-24-032)
NINDS Leads ADRD Research Priority-Setting Planning Efforts
NINDS-led ADRD summits represent a continuous decade long planning effort. ADRD summits occur every three years and respond to the National Plan to Address Alzheimer’s Disease (“National Plan”) that was released in 2012 and updated annually. These Summits set national research recommendations with timelines that reflect critical scientific priorities for research on ADRD. During each ADRD Summit planning process, the established prioritized recommendations are updated, and developed further, under the leadership of the ADRD Summit Steering Committee, which includes a Working Group of the NANDS Council. The Committee solicits input from nationally and internationally recognized dementia-science experts, as well as public and private stakeholders. The resulting recommendations guide ADRD research for the next several years. Links to NANDS Council-approved ADRD Summit Reports are provided below.
| Summit Year | Document Title | |
|---|---|---|
| 2022 | ADRD Summit 2022 FACA Report(pdf, 3804 KB) | ADRD Summit 2022 Research Milestones and Success Criteria(pdf, 512 KB) |
| 2019 | ADRD Summit 2019 FACA Report(pdf, 2131 KB) | ADRD Summit 2019 Research Milestones and Success Criteria |
| 2016 | ADRD Summit 2016 FACA Report(pdf, 922 KB) | ADRD Summit 2016 Research Milestones and Success Criteria; Proceedings Article |
| 2013 | ADRD Summit 2013 FACA Report(pdf, 980 KB) | ADRD Summit 2013 Research Milestones and Success Criteria; Proceedings Article |
NIH Estimates of Funding for Various Research, Condition, and Disease Categories
| Research/Disease Areas* | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 (Estimated) |
|---|---|---|---|---|---|
| Alzheimer's Disease Including Alzheimer's Disease Related Dementias (AD/ADRD) | $2,869 | $3,251 | $3,514 | $3,761 | $3,871 |
| Alzheimer's Disease | $2,683 | $3,059 | $3,314 | $3,538 | $3,627 |
| Frontotemporal Dementia | $166 | $164 | $169 | $198 | $198 |
| Lewy Body Dementia | $84 | $113 | $118 | $118 | $118 |
| Vascular Contributions to Cognitive Impairment and Dementia | $362 | $455 | $445 | $535 | $535 |
*Dollars in millions and rounded
To learn more about NIH Investment in AD/ADRD, please visit the Categorical Spending site and enter "Alzheimer's Disease Including Alzheimer's Disease Related Dementias".
Contacts
Amber McCartney | Scientific Project Manager
amber.mccartney@nih.gov
Arvind Shukla | Scientific Program Manager
arvind.shukla@nih.gov
Herson Rene Astacio Cuevas | Health Program Specialist
herson.astacio@nih.gov
Kiara Bates | Program Specialist
kiara.bates@nih.gov
AD+ADRD Research Implementation Milestones database
The AD+ADRD Research Implementation Milestones database is a research framework detailing specific steps and success criteria towards achieving the goal of the National Plan to Address Alzheimer's Disease: to treat and prevent AD and ADRDs by 2025. This database includes research milestones and responsive activities for the NIH triennial AD, ADRD, and Dementia Care, Services and Supports research summits.
International Alzheimer's and Related Dementias Research Portfolio
IADRP reports categories of funded research supported by public and private organizations both in the US and abroad all categorized using the Common Alzheimer's and Related Dementias Research Ontology (CADRO)